Skip to main content
Premium Trial:

Request an Annual Quote

Following Spring Cleaning, Paradigm Genetics Posts Increased Losses, Lower Revenues

NEW YORK, Aug. 12-Paradigm Genetics today reported increased losses and declining revenues for the second quarter of 2002.

 

Net loss for the quarter was $5 million or $0.16 per share, compared to a net loss of $4.3 million or $0.16 per share in the same quarter of 2001.

 

Revenues fell by 13 percent to $5.3 million for the quarter from $6.1 million in the first quarter of 2001, a slump caused by a slowdown in Paradigm's commercial partnership with Bayer. The company said this decline was partly offset by new revenues from its December 2001 purchase of the plant genomics firm ParaGen.

 

Including stock-based compensation expenses, the company spent $7.6 million on R&D in the quarter, up from $6.9 million in the second quarter last year.

 

As of June 30, 2002, Paradigm held $9.6 million in cash, cash equivalents and short-term investments.

 

Earlier this spring, Paradigm launched a house-cleaningthat laid off 20 percent of the workforce and replaced founder and CEO John Ryals with Syngenta executive Heinrich Gugger.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more